-
Shenzhen TargetRx Raises $50M in Series C Financing for Global Clinical Trials
•
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of a Series C financing round, raising USD 50 million. The funds will be used to advance overseas clinical studies for multiple innovative drugs, positioning the company for global expansion. Company Background and PipelineFounded in 2014,…
-
Jiangsu Simcere Acquires Exclusive Rights to TargetRx’s TGRX-326 in Licensing Deal
•
SHENZHEN—Shenzhen TargetRx, Inc., a leading developer of small-molecule kinase inhibitors, has entered into a licensing agreement with Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a fellow Chinese pharmaceutical company. The deal concerns TargetRx’s TGRX-326, an ALK/ROS1 dual receptor tyrosine kinase inhibitor currently at the clinical stage. According to the agreement,…
-
Shenzhen TargetRx’s TGRX-678 Set to Receive Breakthrough Therapy Designation for CML-AP
•
Shenzhen TargetRx, Inc., a China-based developer of small-molecule kinase inhibitors, is poised to receive breakthrough therapy designation (BTD) for its Bcr-Abl inhibitor, TGRX-678, according to the China Center for Drug Evaluation (CDE) website. This designation recognizes the molecule’s promising potential for treating accelerated chronic myeloid leukemia (CML-AP) in patients who…
-
Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development
•
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions” of renminbi in a Series B financing round, with investors undisclosed. The proceeds will go towards pivotal clinical studies for TGRX-678 and TGRX-326, development of other drug candidates, and product pipeline expansion. Company and ProductsFounded…
